Predicting Survival in Pulmonary Arterial Hypertension
In pulmonary arterial hypertension, which endpoints and risk stratification tools offer the best means of predicting survival?
Pulmonary Arterial Hypertension
RV-Pulmonary Artery Coupling Prognosis in Cardiac Resynchronization Therapy
A study was conducted to evaluate the evolution and prognostic value of TAPSE/PASP ratio in cardiac resynchronization therapy recipients.
PAH in Hispanic Patients: Outcomes and Social Determinants of Health
Among patients with pulmonary arterial hypertension, what is the relationship between Hispanic ethnicity, social determinants of health, and clinical outcomes?
Risk Stratification Scores in Pulmonary Arterial Hypertension
How effective are the 3 most commonly used pulmonary arterial hypertension risk assessment tools — REVEAL, COMPERA, and FPHR — in predicting mortality risk?
ARROW Finds Selonsertib Ineffective for Pulmonary Arterial Hypertension
Because oxidative stress and elevated ASK1 activity appear to play a role in vascular remodeling in PAH, ASK1 inhibition with selonsertib was studied.
An Algorithm for Predicting Inadequate Response to Initial PAH Therapy Developed
Research presented at CHEST 2021 used machine learning to develop an algorithm for predicting poor response to initial PAH therapy, based on claims data.
Inhaled Treprostinil and Lung Function in Patients With PH-ILD and PAH
A post-hoc analysis compared lung function changes in the INCREASE and TRIUMPH trials of inhaled treprostinil for PH-ILD and PAH.
Initial Triple vs Dual Oral Combination Therapy for Newly Diagnosed PAH
A study investigated the efficacy of double or triple pharmacotherapy in pulmonary arterial hypertension.
Inhaled Imatinib Designated Orphan Drug for Pulmonary Arterial Hypertension
AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.
CFTR Expression in the Pathogenesis of Pulmonary Arterial Hypertension
Researchers sought to delineate the role of cystic fibrosis transmembrane conductance regulator (CFTR) in pulmonary arterial hypertension pathogenesis through observational and interventional experiments in human tissues and animal models.
- Loading...
Loading...
Next post in Pulmonary Hypertension
Loading... 
Loading...